Drug Profile
AFC 5128
Alternative Names: AFC-5128; AFC-5261Latest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Affectis Pharmaceuticals
- Developer Affectis Pharmaceuticals; Charcot-Marie-Tooth Association; Merck Serono
- Class
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis; Neuropathic pain
- No development reported Charcot-Marie-Tooth disease
Most Recent Events
- 11 Oct 2023 Preclinical development is ongoing Germany for multiple sclerosis and neuropathic pain
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in multiple sclerosis and neuropathic pain presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023)
- 28 May 2019 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in Germany (PO)